Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug cocktail aims to beat lymphoma without chemo

NCT ID NCT07496229

Disease control Sponsor: Dizal Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests a combination of two drugs, GW5282 and golidocitinib, for people with T-cell lymphoma. The first part finds the safest dose; the second part compares the combo to standard chemotherapy. About 165 adults with newly diagnosed or relapsed disease will take part. The goal is to see if the combo works better and is safer than current treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
GW5282 combined with golidocitinib
What this could lead to
If successful, this could offer a new chemo-free combination therapy for T-cell lymphoma, potentially improving response rates and reducing side effects compared to standard treatment.
What could go wrong
This is an early phase 1/2 trial with a small number of participants, so results may not apply broadly. The combination may cause unexpected side effects or fail to show better outcomes than standard chemo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 165 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Signed informed consent; 2. Adult ≥ 18 years of age; 3. ECOG performance status score ≤ 2; 4. Life expectancy of not less than 12 weeks; 5. Histopathologically confirmed diagnosis of PTCL; 6. Presence of measurable disease; 7. Adequate bone marrow function and vital organ function reserve; 8. Ability to comply with study requirements and to complete study-related procedures; 9. Adequate contraception during participation in the trial. Exclusion Criteria: 1. Presence of unresolved drug-related adverse events greater than Grade 1; 2. Lymphoma involving the central nervous system; 3. Failure to complete the required washout period for other anti-tumor therapies; 4. Corticosteroid use that does not meet protocol requirements; 5. Major surgery/trauma within a short period, or planned major surgery within a short period; 6. Vaccination with a live vaccine within a short period; 7. Inability to discontinue prohibited medications; 8. Requirement for immunosuppressive agents or biologics due to an underlying disease; 9. Presence of active infection; 10. Significant cardiovascular disease; 11. Presence of gastrointestinal disease that might affect drug intake or absorption; 12. History of other malignancies; 13. Known allergy to the study drug; 14. Other severe or uncontrolled systemic diseases; 15. Personnel with a conflict of interest (e.g., site staff, sponsor employees); 16. Pregnant or breastfeeding women; 17. Inability to comply with protocol requirements.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Peripheral T-cell lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

mature T-cell and NK-cell non-Hodgkin lymphoma T-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

T-cell lymphomas

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    12 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Chongqing Cancer Hospital

    NOT_YET_RECRUITING

    Chongqing, Chongqing Municipality, China

  • Fudan University Shanghai Cancer Center

    RECRUITING

    Shanghai, China

  • Fujian Cancer Hospital

    NOT_YET_RECRUITING

    Fuzhou, Fujian, China

  • Guangxi Medical University Cancer Hospital

    NOT_YET_RECRUITING

    Nanning, Guangxi, China

  • Henan Cancer Hospital

    NOT_YET_RECRUITING

    Zhengzhou, China

  • Henan Provincial People's Hospital

    NOT_YET_RECRUITING

    Zhengzhou, Henan, China

  • Nanjing Drum Tower Hospital

    NOT_YET_RECRUITING

    Nanjing, Jiangsu, China

  • Shanxi Provincial Cancer Hospital

    NOT_YET_RECRUITING

    Taiyuan, China

  • Taizhou Hospital of Zhejiang Province

    NOT_YET_RECRUITING

    Taizhou, Zhejiang, China

  • The First Affiliated Hospital of Wenzhou Medical University

    NOT_YET_RECRUITING

    Wenzhou, Zhejiang, China

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    NOT_YET_RECRUITING

    Wuhan, Hubei, China

  • West China Hospital of Sichuan University

    NOT_YET_RECRUITING

    Chengdu, Sichuan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.